Table 4.
Model 2.0 (M2.0) | Model 2.1 | Model 2.2 | Model 2.3 | Model 2.4 | Model 2.5 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
M2.0 + perf. Status | M2.0 + AML ontogeny | M2.0 + WBC | M2.0 + cytogen. Progn. | Fully adjusted | ||||||||||||
OR | [95% CI] | OR | [95% CI] | OR | [95% CI] | OR | [95% CI] | OR | [95% CI] | OR | [95% CI] | |||||
Age | 0.79 | [0.76; 0.82] | 0.79 | [0.76; 0.82] | 0.76 | [0.73; 0.80] | 0.77 | [0.74; 0.81] | 0.76 | [0.73; 0.80] | 0.74 | [0.70; 0.79] | ||||
Sex | Men | ref | ref | ref | ref | ref | ||||||||||
Women | 0.65 | [0.40; 1.05] | 0.65 | [0.40; 1.04] | 0.61 | [0.36; 1.03] | 0.73 | [0.44; 1.22] | 0.84 | [0.50; 1.44] | 0.71 | [0.40; 1.24] | ||||
Patients’ SEP (quintile of deprivation score) | Q1 – least | ref | ref | Ref | ref | ref | ||||||||||
Q2 | 0.46 | [0.22; 0.99] | 0.46 | [0.21;0.99] | 0.52 | [0.23; 1.17] | 0.43 | [0.20; 0.96] | 0.47 | [0.20; 1.09] | 0.47 | [0.20; 1.14] | ||||
Q3 | 0.98 | [0.49; 1.95] | 0.97 | [0.48; 1.95] | 1.07 | [0.51; 2.25] | 0.97 | [0.47; 2.01] | 0.77 | [0.36; 1.65] | 1.08 | [0.48; 2.41] | ||||
Q4 | 0.55 | [0.28; 1.08] | 0.56 | [0.28; 1.12] | 0.58 | [0.28; 1.20] | 0.54 | [0.27; 1.09] | 0.45 | [0.21; 0.96] | 0.58 | [0.26; 1.27] | ||||
Q5 – most | 0.41 | [0.19; 0.90] | 0.45 | [0.20; 0.98] | 0.59 | [0.25; 1.40] | 0.40 | [0.17; 0.93] | 0.45 | [0.19; 1.07] | 0.60 | [0.23; 1.53] | ||||
Charlson comorbidity index | 0 | ref | ref | ref | ref | ref | ||||||||||
1 | 0.61 | [0.33; 1.13] | 0.63 | [0.34; 1.17] | 0.66 | [0.34; 1.29] | 0.58 | [0.30; 1.10] | 0.70 | [0.36; 1.37] | 0.69 | [0.34; 1.40] | ||||
2+ | 0.64 | [0.35; 1.17] | 0.66 | [0.35; 1.22] | 1.05 | [0.54; 2.03] | 0.55 | [0.29; 1.05] | 0.59 | [0.30; 1.15] | 1.06 | [0.52; 2.18] | ||||
Undefinable | 0.14 | [0.06; 0.35] | 0.18 | [0.07; 0.46] | 0.19 | [0.07; 0.50] | 0.13 | [0.05; 0.32] | 0.31 | [0.12; 0.82] | 0.18 | [0.06; 0.55] | ||||
Performance status | 0/1 | ref | Ref | |||||||||||||
2 | 0.45 | [0.23; 0.86] | 0.38 | [0.18; 0.81] | ||||||||||||
3/4 | 0.77 | [0.34; 1.74] | 0.3 | [0.11; 0.82] | ||||||||||||
Undefinable | 0.6 | [0.27; 1.36] | 0.74 | [0.30; 1.83] | ||||||||||||
AML ontogeny | AML de novo | ref | ref | |||||||||||||
Secondary (post MDS or post treatment) | 0.13 | [0.07; 0.23] | 0.12 | [0.06; 0.22] | ||||||||||||
Undefinable | Not estimated | Not estimated | ||||||||||||||
White blood cell (WBS) counts (tercile) | Tercile 1 – low | Ref | ref | |||||||||||||
Tercile 2 – intermediate | 1.5 | [0.82; 2.75] | 1.86 | [0.95; 3.65] | ||||||||||||
Tercile 3 – high | 5.74 | [3.06; 10.79] | 7.83 | [3.82; 16.08] | ||||||||||||
Undefinable a | Not estimated | Not estimated | ||||||||||||||
Cytogenetic prognosis | Favorable/Intermediate | ref | ref | |||||||||||||
Unfavorable | 0.14 | [0.08; 0.25] | 0.12 | [0.06; 0.22] | ||||||||||||
Undefinable a | Not estimated | Not estimated |
Models are adjusted for each confounder, and fully adjusted. Generalized linear model with logit link function, adjusted odds ratios [95% Confidence Intervals] (N = 592)
athe perfect predictor of outcome “undefinable” AML ontogeny, White blood cell counts, and cytogenetic prognosis were retained in the models to avoid reducing sample size, but OR and 95%CI were not estimated